Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Spigel

Showing results (61-70 of 220) with videos related to

Pageof 22
Sort By:
Clinical Lung Cancer|April 3, 2017
An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung CancerDavid R Spigel, Alexander Luft, Henrik Depenbrock, et al.
Cancer Investigation|April 28, 2012
Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumorsSuzanne F Jones, Jeffrey R Infante, David R Spigel, et al.
Cancer|February 17, 2018
Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2David R Spigel, John D Hainsworth, Mathew J Joseph, et al.
Clinical Breast Cancer|July 25, 2008
A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancerDenise A Yardley, Howard A Burris, Cindy P Farley, et al.
Future Oncology (London, England)|December 15, 2025
Impact of community recruitment and inclusion initiatives on enrollment in the biomarker-driven MyTACTIC trialRichard M Zuniga, Ari VanderWalde, Lee S Schwartzberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2014
Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 studySilvia Novello, Giorgio V Scagliotti, Oleksandr Sydorenko, et al.
Clinical Breast Cancer|October 28, 2008
A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancerDenise A Yardley, Howard A Burris, Lisa Simons, et al.
Clinical Lung Cancer|June 14, 2011
A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancerDavid R Spigel, F Anthony Greco, Howard A Burris, et al.
Investigational New Drugs|October 23, 2014
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancerJohanna C Bendell, Suzanne F Jones, Lowell Hart, et al.
Investigational New Drugs|May 12, 2023
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumorsGerald S Falchook, Jasgit Sachdev, Esteban Rodrigo Imedio, et al.
Pageof 22

Showing results (61-70 of 220) with videos related to

Sort By:
Pageof 22
Clinical Lung Cancer|April 3, 2017
An Open-Label, Randomized, Controlled Phase II Study of Paclitaxel-Carboplatin Chemotherapy With Necitumumab Versus Paclitaxel-Carboplatin Alone in First-Line Treatment of Patients With Stage IV Squamous Non-Small-Cell Lung CancerDavid R Spigel, Alexander Luft, Henrik Depenbrock, et al.
Cancer Investigation|April 28, 2012
Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumorsSuzanne F Jones, Jeffrey R Infante, David R Spigel, et al.
Cancer|February 17, 2018
Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2David R Spigel, John D Hainsworth, Mathew J Joseph, et al.
Clinical Breast Cancer|July 25, 2008
A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancerDenise A Yardley, Howard A Burris, Cindy P Farley, et al.
Future Oncology (London, England)|December 15, 2025
Impact of community recruitment and inclusion initiatives on enrollment in the biomarker-driven MyTACTIC trialRichard M Zuniga, Ari VanderWalde, Lee S Schwartzberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2014
Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 studySilvia Novello, Giorgio V Scagliotti, Oleksandr Sydorenko, et al.
Clinical Breast Cancer|October 28, 2008
A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancerDenise A Yardley, Howard A Burris, Lisa Simons, et al.
Clinical Lung Cancer|June 14, 2011
A phase II study of higher dose weekly topotecan in relapsed small-cell lung cancerDavid R Spigel, F Anthony Greco, Howard A Burris, et al.
Investigational New Drugs|October 23, 2014
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancerJohanna C Bendell, Suzanne F Jones, Lowell Hart, et al.
Investigational New Drugs|May 12, 2023
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumorsGerald S Falchook, Jasgit Sachdev, Esteban Rodrigo Imedio, et al.
Pageof 22